L01EL03 zanubrutinib
ATC group of level 5 – chemical substance · in plain English: targeted cancer medicines (kinase inhibitors)
This site has the patient leaflet or the SPC of 2 medicines in this group.
- 2 prescription only (POM)
Active substance: Zanubrutinib – all medicines with this substance, also in combinations.
Place in the ATC classification
- L Antineoplastic and immunomodulating agents 1,791 medicines
- L01 Antineoplastic agents 1,025 medicines
- L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 353 medicines
- L01EL Bruton's tyrosine kinase (BTK) inhibitors 8 medicines
- L01EL03 zanubrutinib 2 medicines
- L01EL Bruton's tyrosine kinase (BTK) inhibitors 8 medicines
- L01E Protein kinase inhibitors, antineoplastic and immunomodulating agents 353 medicines
- L01 Antineoplastic agents 1,025 medicines
Medicines
| Medicine | Legal category |
|---|---|
| Brukinsa 160 mg film-coated tablets | Prescription only (POM) |
| Brukinsa 80 mg hard capsules SPC | Prescription only (POM) |
Other groups of the same level
- L01EL01 ibrutinib 5 medicines
- L01EL02 acalabrutinib 1 medicine
Other names of the ATC group
- German: L01EL03 Zanubrutinib
- Turkish: L01EL03 zanubrutinib
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group L01EL03
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.